Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MEDI6383 · 1 trial · 1 indication
Primary endpoint will be the number (%) of subjects with adverse events and serious adverse events.
| Arm | Type | Description |
|---|---|---|
| Monotherapy Arm | EXPERIMENTAL | MEDI6383 |
| Combination Arm | EXPERIMENTAL | MEDI6383 and MEDI4736 |
| Name | Type | Description |
|---|---|---|
| MEDI6383 | BIOLOGICAL | Subjects will receive MEDI6383 until disease progression or adverse event. |
| MEDI6383 and MEDI4736 | BIOLOGICAL | Subjects will recieve MEDI6383 and MEDI4736 until disease progression or adverse event. |
Inclusion Criteria: 1. Male and female subjects; age ≥ 18 2. Written informed consent must be obtained 3. Subjects must meet the following criteria: 1. Have recurrent or metastatic solid tumors 2. Must have received and have progressed, are refractory, or are intolerant to standard therapy a...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
MEDI6383 is an investigational monoclonal antibody being studied for the treatment of recurrent or metastatic solid tumors. It is intended for adult patients with select advanced solid tumors, as evaluated in a Phase 1 clinical trial.
MEDI6383 is being developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker symbol AZN. The company is conducting clinical research to evaluate the safety and efficacy of this investigational therapy.
MEDI6383 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied in clinical trials to assess its safety and potential efficacy in patients with advanced solid tumors.
MEDI6383 has been studied in a Phase 1 clinical trial with the identifier NCT02221960. This trial evaluated MEDI6383 alone and in combination with MEDI4736 in adult subjects with select advanced solid tumors. The trial was completed and enrolled 39 participants.
No, MEDI6383 is not the same as MEDI4736. MEDI6383 is a separate investigational monoclonal antibody. In clinical trial NCT02221960, MEDI6383 was studied both alone and in combination with MEDI4736, which is another investigational agent developed by AstraZeneca.